C Number:

Study Gender:

PWG Approval Date

R11: Fetal Defect Summary Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3

MOG003B

Both See web page for date of PWG Approval Date Report Requested: 01/14/2020 Time Report Requested: 12:18:07 Lab: RTI

R11: Fetal Defect Summary Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3

Date Report Requested: 01/14/2020 Time Report Requested: 12:18:07 Lab: RTI

F1 Female: Prenatal Female						
	Treatment Groups (ppm)					
	0	1000	3000	6000		
	All Exam	s				
No. Fetuses	283	229	183	218		
No. Litters	19	17	12	16		
Malformation						
Affected fetuses	11 (3.89)	1 (0.44) **	4 (2.19)	6 (2.75)		
Affected litters	6 (31.58)	1 (5.88)	2 (16.67)	3 (18.75)		
/ariation						
Affected fetuses	54 (19.08)	28 (12.23) *	26 (14.21)	49 (22.48)		
Affected litters	15 (78.95)	13 (76.47)	10 (83.33)	12 (75.00)		
Gross Finding						
Affected fetuses	0 (0.00)	2 (0.87)	0 (0.00)	0 (0.00)		
Affected litters	0 (0.00)	1 (5.88)	0 (0.00)	0 (0.00)		
	External					
lo. Fetuses	283	229	183	218		
lo. Litters	19	17	12	16		
<i>Malformation</i>						
Affected fetuses	1 (0.35)	0 (0.00)	0 (0.00)	1 (0.46)		
Affected litters	1 (5.26)	0 (0.00)	0 (0.00)	1 (6.25)		
Bross Finding						
Affected fetuses	0 (0.00)	2 (0.87)	0 (0.00)	0 (0.00)		
Affected litters	0 (0.00)	1 (5.88)	0 (0.00)	0 (0.00)		

R11: Fetal Defect Summary Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3

Date Report Requested: 01/14/2020 Time Report Requested: 12:18:07 Lab: RTI

F1 Female: Prenatal Female					
Treatment Groups (ppm)					
0	1000	3000	6000		
Visceral					
283	229	183	218		
19	17	12	16		
9 (3.18)	1 (0.44) *	4 (2.19)	5 (2.29)		
5 (26.32)	1 (5.88)	2 (16.67)	2 (12.50)		
36 (12.72)	19 (8.30)	15 (8.20)	24 (11.01)		
13 (68.42)	9 (52.94)	9 (75.00)	11 (68.75)		
Head					
142	116	94	107		
19	17	12	16		
	0 Visceral 283 19 9 (3.18) 5 (26.32) 36 (12.72) 13 (68.42) Head 142	Treatment G 0 1000 Visceral 283 229 19 17 9 (3.18) 1 (0.44) * 5 (26.32) 1 (5.88) 36 (12.72) 19 (8.30) 13 (68.42) 9 (52.94) Head 142 142 116	Treatment Groups (ppm) 0 1000 3000 Visceral Visceral 283 229 183 19 17 12 9 (3.18) 1 (0.44) * 4 (2.19) 5 (26.32) 1 (5.88) 2 (16.67) 36 (12.72) 19 (8.30) 15 (8.20) 13 (68.42) 9 (52.94) 9 (75.00) Head 142 116 94		

NO VISIBLE LESIONS PRESENT

R11: Fetal Defect Summary Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3

Date Report Requested: 01/14/2020 Time Report Requested: 12:18:07 Lab: RTI

F1 Female: Prenatal Female					
	Treatment Groups (ppm)				
	0	1000	3000	6000	
	Skeletal - Bo	dy			
No. Fetuses	283	211	183	218	
No. Litters	19	17	12	16	
Malformation					
Affected fetuses	1 (0.35)	0 (0.00)	0 (0.00)	0 (0.00)	
Affected litters	1 (5.26)	0 (0.00)	0 (0.00)	0 (0.00)	
Variation					
Affected fetuses	21 (7.42) ** #	12 (5.69)	13 (7.10)	30 (13.76) *	
Affected litters	8 (42.11)	7 (41.18)	5 (41.67)	10 (62.50)	
	Skeletal - Sk	ull			
No. Fetuses	141	104	89	111	
No. Litters	19	17	12	16	

NO VISIBLE LESIONS PRESENT

Date Report Requested: 01/14/2020 Time Report Requested: 12:18:07 Lab: RTI

LEGEND

Upper row denotes number of affected fetuses (%) and lower row the number of affected litters (%)

Trend and pairwise significance levels are determined using one-sided tests.

Statistical analysis for litter data and for fetal data ignoring the litter effects were performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) tests.

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

Statistical analysis for fetal data including litter effects were performed by using a Rao-Scott modification to the Cochran-Armitage test where the Dam ID was the random effect for both trend and pairwise analysis.

Statistically significant at P <= 0.05 (litter based analysis)

Statistically significant at P <= 0.01 (litter based analysis)

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

** END OF REPORT **